Compare ACDC & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | SGP |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2021 | 2026 |
| Metric | ACDC | SGP |
|---|---|---|
| Price | $3.17 | $33.04 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.16 | ★ $46.33 |
| AVG Volume (30 Days) | ★ 1.9M | 99.4K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,941,800,000.00 | N/A |
| Revenue This Year | $1.38 | N/A |
| Revenue Next Year | $17.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.61 | $17.06 |
| 52 Week High | $8.22 | $39.92 |
| Indicator | ACDC | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 37.30 | 55.62 |
| Support Level | $2.61 | $25.28 |
| Resistance Level | $5.41 | N/A |
| Average True Range (ATR) | 0.46 | 2.38 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 21.49 | 34.54 |
ProFrac Holding Corp is a technology-focused, vertically integrated energy services company providing hydraulic fracturing, proppant production, completion services, and related products, including distributed power generation, to upstream oil and natural gas companies in the United States. The Company operates through four segments: Stimulation Services, Proppant Production, Manufacturing, and Flotek. The Stimulation Services segment, which generates maximum revenue, provides hydraulic fracturing services using mobile units and auxiliary equipment. The Proppant Production segment supplies proppant, the Manufacturing segment sells engineered products such as pumps, valves, and piping, and Flotek is a chemistry and data technology company serving the E&P industry.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.